Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Mai 2019 16:15 ET | Quelle: Novan, Inc.

Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
20. August 2018 06:30 ET | Quelle: Novan, Inc.

Novan Announces Promising Clinical Results with SB414

In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
15. Mai 2018 08:10 ET | Quelle: Novan, Inc.

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
05. Dezember 2017 08:35 ET | Quelle: Novan, Inc.

Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
18. Oktober 2017 07:05 ET | Quelle: Novan, Inc.

Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
27. April 2017 09:05 ET | Quelle: Novan, Inc.

Novan Presents Preclinical Data from Inflammatory Skin Diseases Program

MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...